Raafay Sophie, MD
Ophthalmology · Grand Blanc, MINPI 1285044107
Payments from drug & device makers
What this record shows
14 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 42.4% of the total. Reporting peaked in 2019 at $2,454 and has fallen 78.3% since, to $532 in 2025.
Across 57 payments — averaging $101.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$2K
- Alimera Sciences, Inc.$2K
- Eyepoint US, Inc.$249
- Regeneron Healthcare Solutions, Inc.$241
- Dutch Ophthalmic, USA$232
- ANI Pharmaceuticals, Inc.$227
- plus $671 from 8 others
Across 48 payments — averaging $4089.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$152K
- Roche TCRC, Inc.$28K
- Astellas Pharma Global Development$10K
- AbbVie$7K
What the payments were for
- Speaking & faculty fees$2,45442%
- Food & beverage$3,33458%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 1 | $2,454 |
| Alimera Sciences, Inc. | 14 | $1,714 |
| Eyepoint US, Inc. | 2 | $249 |
| Regeneron Healthcare Solutions, Inc. | 9 | $241 |
| Dutch Ophthalmic, USA | 2 | $232 |
| ANI Pharmaceuticals, Inc. | 7 | $227 |
| Genentech USA, Inc. | 9 | $222 |
| Astellas Pharma US Inc | 6 | $157 |
| Carl Zeiss Meditec USA, Inc. | 2 | $145 |
| AbbVie | 1 | $78 |
| Astellas Pharma Global Development | 1 | $21 |
| Rxsight Inc | 1 | $16 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucentis$2,454
- Iluvien$1,515
- YUTIQ$1,412
- EVA, combined machine$172
- TISSUEBLUE$172
How this compares
$5,788 in reported general payments places this provider in the 85th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 188 | $9,357 |
| Ketorolac Tromethamine | 154 | $5,527 |
| Difluprednate | 40 | $3,594 |
| Bromfenac Sodium | 12 | $2,407 |
| Brimonidine Tartrate | 99 | $1,682 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 59 | $1,300 |
| Ciprofloxacin Hcl | 81 | $859 |
| Latanoprost | 24 | $413 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Grand Blanc
- Christopher SinghGrand Blanc$13K
- Ankur MehtaGrand Blanc$11K
- Amy ZhangGrand Blanc$10K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.